Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Shares Outstanding (Weighted Average) (2024 - 2025)

Kairos Pharma's Shares Outstanding (Weighted Average) history spans 2 years, with the latest figure at $18.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 62.27% year-over-year to $18.4 million; the TTM value through Dec 2025 reached $18.4 million, up 62.27%, while the annual FY2025 figure was $18.4 million, 62.27% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $18.4 million in Q4 2025 per KAPA's latest filing, up from $17.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $18.4 million in Q4 2025 to a low of $278188.0 in Q3 2024.